Biotech projects win five R&D Start grants
Friday, 11 March, 2005
Five biotechnology projects were amongst $19 million worth of AusIndustry R&D Start grants announced today by federal industry minister Ian Macfarlane.
The biggest winner was Sydney biotech Gropep (ASX:GRO) which received $3.3 million for the development of PP0102, its topically administered peptide treatment for psoriasis.
Sydney diagnostics company Medsaic will receive $1.5 million towards the development of its platform technology for the diagnosis of blood borne and solid tissue diseases.
Other grants were awarded to:
- Coridon, for a human herpesvirus (HSV) DNA Vaccine ($1.5 million)
- Vital Health Sciences, for a transdermal delivery system for morphine ($1.7 million)
- Plantic Technologies, for the development of high performance biodegradable films for consumer goods applications ($1.7 million)
Tasmania grabs 3 Commercial Ready grants
Three Tasmanian companies are among the very first projects to be awarded funding under the government's new Commercial Ready program. The successful companies were:
- Verdant, which received $1 million to develop new sensing technology to improve understanding and mastering of complex fisheries and aquaculture systems
- Marinova, which received $894,237 to work on a new process for producing high-value bio-therapeutic products from seaweed
- Serve-Ag, which received $500,706 to develop environmental and plant nutrition monitoring products for crop-based agriculture
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
